ALK and non-small cell lung carcinoma: The long term outcomes for metastatic NSCLC patients are poor despite significant therapeutic advances including the availability of small molecule inhibitors against epidermal growth factor receptor tyrosine kinases (EGFR-TK), anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 receptor tyrosine kinase (ROS1) because majority of patients report drug resistance [3, 4].